CRBU (Caribou Biosciences) Cash-to-Debt : 7.95 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Caribou Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Caribou Biosciences's cash to debt ratio for the quarter that ended in Mar. 2025 was 7.95.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Caribou Biosciences could pay off its debt using the cash in hand for the quarter that ended in Mar. 2025.

The historical rank and industry rank for Caribou Biosciences's Cash-to-Debt or its related term are showing as below:

CRBU' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.91 Med: 10.83 Max: No Debt
Current: 7.95

During the past 6 years, Caribou Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 7.91. And the median was 10.83.

CRBU's Cash-to-Debt is ranked better than
50.48% of 1464 companies
in the Biotechnology industry
Industry Median: 7.685 vs CRBU: 7.95

Caribou Biosciences Cash-to-Debt Historical Data

The historical data trend for Caribou Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Caribou Biosciences Cash-to-Debt Chart

Caribou Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

10.11

No Debt

8.93

12.13

7.91

Caribou Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash-to-Debt	Get a 7-Day Free Trial															10.83	9.77	8.57	7.91	7.95

Competitive Comparison of Caribou Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Caribou Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caribou Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Caribou Biosciences's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Caribou Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Caribou Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	209.537	/	(1.426	+	25.061)
	=	7.91

Caribou Biosciences's Cash to Debt Ratio for the quarter that ended in Mar. 2025 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	208.465	/	(1.901	+	24.323)
	=	7.95

Caribou Biosciences (NAS:CRBU) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Caribou Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Caribou Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Caribou Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caribou Biosciences Inc (NAS:CRBU) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 7th Street, Suite 105, Berkeley, CA, USA, 94710

Website

https://www.cariboubio.com

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Executives

Rachel E. Haurwitz	director, officer: See Remarks	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ruhi Ahmad Khan	officer: Chief Business Officer	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Barbara G Mcclung	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Steven Kanner	officer: See Remarks	CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Syed Ali-aamir Rizvi	officer: Chief Medical Officer	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ryan Fischesser	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
David Lee Johnson	director	C/O GLOBAL BLOOD THERAPEUTICS, 171 OYSTER POINT BLVD, STE. 300, SAN FRANCISCO CA 94080
Dara Richardson-heron	director	C/O CARIBOU BIOSCIENCES, INC., 29, BERKELEY CA 94710
Ran Zheng	director	2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Nancy Whiting	director	2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Natalie Sacks	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Andrew Guggenhime	director	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Jason O'byrne	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710